of TACE-EBRT, without affecting the efficacy and tolerance of sorafenib. The description of the patients suggests an absence of significant differences between arms at baseline but it does not discard the possibility of a higher proportion of patients having a combination of poor predictors of tolerance, efficacy, and survival (bilobar disease, main portal vein invasion, and performance status 1) in one arm. An additional aspect that is not detailed is the status (cirrhotic versus non-cirrhotic) of the underlying liver of patients in each group. Patients with HCC related to infection with the hepatitis B virus might not have cirrhosis and this affects the prognosis and risk of adverse events. Even if all patients had underlying cirrhosis and were classified as having Child-Pugh class A disease, the potential for heterogeneity persists. Child-Pugh class A disease might include patients with ascites, a known predictor of poor tolerance of therapy and inferior survival. This heterogeneity might explain why only 63% of the patients in the TACE-EBRT arm received TACE, while the rest received chemotherapy suspended in lipiodol without embolization 4 . In a trial with a larger sample size, such potential imbalances might be less relevant, but in a trial with a small cohort, some form of stratification before randomization could have been worth considering. This approach would enable a better understanding of the results and prime the development of more-refined trial designs that enable further evaluation of TACE-EBRT with overall survival as the primary end point. Obviously, the current availability of several systemic agents in the first and second lines of treatment adds a greater level of complexity in terms of trial design and analysis. However, the existence of such complexity should not avoid the need to use a robust end point. The feasibility of such an undertaking has been proved in three trials comparing the efficacy of radioembolization with that of sorafenib [8] [9] [10] . These comments should not be seen as a negative opinion about the value of the investigation. Evaluation of new locoregional interventions is an appealing area of research and these efforts should be acknowledged. Ultimately, step by step assessments until reaching conclusive proof of benefit should 
N e w s & V i e w s
The gynaecological oncology community faces two issues: the rising endometrial cancer rates in response to mounting obesity and longevity, and the continued diagnosis of ovarian cancer at an advanced stage, which results in a high case-fatality ratio, despite concerted worldwide efforts for early diagnosis. The currently available screening tests for both cancer types lack specificity. To address this unmet need, Wang and collaborators 1 refined the proof-of-principle test that they had previously developed to detect tumour cell-free DNA (cfDNA) in liquid-based cytology (Pap) specimens from patients with endometrial or ovarian cancer 2 . In their new test, PapSEEK, these investiga tors included multiplex PCR to detect mutations in 18 genes and assays to detect aneuploidy 1 . In a retrospective case-control study of 1,658 individuals, the sensitivity for the detection of endometrial cancer was 81%, and 33% for ovarian cancer. By using additional
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PapSEEK , a novel liquid-based cytology test, enabled the highly specific detection of endometrial and ovarian cancer in a retrospective study. Herein, I discuss potential applications of this tool, both for cancer screening of asymptomatic populations and for the early diagnosis of cancer in symptomatic women. 
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second-line test, such as PapSEEK using Tao and Pap brush and plasma DNA samples, could substantially shorten the time from first-line testing to diagnosis. This improvement would be particularly relevant if a definitive mortality reduction was found in 2019 at the end of extended follow-up of the UKCTOCS cohort.
Unlike in the general population, the combined screening approach involving the Tao brush and cervical cytology could be of immediate relevance to women at high risk of developing endometrial cancer (for example, those with Lynch syndrome). These women are offered endometrial cancer screeningoften involving annual endometrial sampling -following a discussion of advantages and disadvantages. In this context, less-invasive testing of Pap samples using PapSEEK could be an attractive and more acceptable alternative for some women. In women at high risk of ovarian cancer (such as those with BRCA mutations), no clear consensus exists regarding screening. Risk-reducing salpingooophorectomy is the recommended approach. Evaluation of PapSEEK in samples taken before surgery from such patients -who have a 6% prevalence of unexpected adnexal neoplasia 9 -could provide preliminary data on performance characteristics. In this population, specificity is likely to be lower than in the general population, because these women are likely to develop other cancers (for example, breast, pancreas, or bowel cancer); however, any associated unnecessary surgery is less of an issue in this setting.
Another area in which PapSEEK could be of great value is in the triage of women with ovarian cancer 'alert' symptoms, such as persistent abdominal or pelvic pain, bloating or increase in abdominal girth, or feeling 'full' quickly. In these women, disease burden is higher than in asymptomatic women and, hence, sensitivity might be similar to that noted in the study (63%) discussed herein 1 . Both plasma and liquid cytology samples can be collected easily at primary care centres, and positive results could enable fast tracking to specialist gynaecological oncology centres. In older women, positive PapSEEK results might result from the presence of other cancers. Hence, if findings are normal on transvaginal ultrasonography, CT imaging of chest, abdomen and pelvis, and mammography are required to identify the source of the detected genetic alterations 8 . In the future, however, methylation-profiling of the tumour cfDNA could provide insights into the tissue of origin and thus tumour location 10 . Finally, the use of PapSEEK on liquid cytology specimens might be a useful tool in health-care settings where women with biospecimens (intrauterine samples obtained with a Tao brush for endometrial cancer and plasma samples for ovarian cancer) they were able to increase the sensitivity to 93% and 63%, respectively. The PapSEEK test had high specificity (~99%), a key requirement for cancer screening 1 . However, in this respect, it needs to be noted that women in the control cohort were much younger (median ages 34 years and 29 years in the Pap and Tao brush cohorts, respectively) than patients with cancer (median ages 68 years and 57 years in the endometrial and ovarian cancer cohorts, respectively). With increasing age, the possibility of detecting mutations is likely to increase, owing to the increased incidence of both cancer-related mutations and other unrelated conditions. In addition, the control cohorts only included women who had not been diagnosed with any cancer. Population screening, however, would involve all individuals, including those with other cancers. The next step in the evaluation of PapSEEK would be to assess performance characteristics in prospective cohort studies, the design of which would depend on the specific application -screening of asymptomatic populations or early detection of cancer in symptomatic women.
The incidence of endometrial cancer is rising, but >75% of women survive 10 years or longer after diagnosis, and most of them are diagnosed at an early stage 3, 4 . This mostly favourable disease course, together with the low specificity of the currently available transvaginal ultrasound test (~85% for an endometrial thickness cut-off of 5 mm (reF.
5
)), makes endometrial cancer screening in the general population difficult to justify. The use of PapSEEK, however, would not require the implementation of an entirely new endometrial cancer screening programme; it would only involve an additional highly specific test on the liquid cytology samples already collected during cervical cancer screening. If such tests were limited to women aged >45 years -the age at which the incidence of endometrial cancer begins to rise 3, 4 -then this strategy might prove to be cost-effective, especially as there has been a small but steady increase (1.6% per year 3, 4 ) in uterine cancer mortality rates over the past decade. This test could become a true game changer if, in the future, it were to include unique DNA signatures associated with progression of precursor lesions to malignancy.
In ovarian cancer, diagnosis at predominantly advanced stages, high case-fatality ratios, and the lack of a definitive mortality reduction with current screening strategies has fuelled the hunt for more effective approaches. The use of PapSEEK on liquid cytology specimens would inevitably include ovarian cancer screening. Although the sensitivity is low (33%) 1 , this strategy would improve the cost-benefit ratio of testing cervical cytology samples. Prospective cohort studies are needed to evaluate the cost effectiveness of increasing sensitivity by testing additional plasma and/or intrauterine samples. Given that high-grade serous ovarian cancers can remain on average >4 years as in situ, stage I, or stage II cancers 6 , the screening frequency might be decreased from annual to once every 2-3 years. Finally, randomized controlled trials would need to be undertaken to evaluate the impact of PapSEEK on ovarian cancer mortality. PapSEEK for detection of ovarian cancer is based on the transit of tumour cfDNA from the tubes and ovaries into the lower genital tract and, thus, it cannot be used in women in whom the tract has been interrupted by common procedures such as tubal ligation, hysterectomy, endometrial ablation, and possibly intrauterine device placement. A limitation with plasma samples is that circu lating cfDNA concentrations vary depending on how the blood is processed and the interval of time from collection to analysis.
In the randomized controlled trial of the UK Ovarian Cancer Screening (UKCTOCS) initiative 7 , multimodal screening of women in the general population using serial serum cancer antigen 125 (CA125; also known as MUC16) levels as a first-line test resulted in high sensitivity (~85%), significant increase in diagnosis of early stage invasive epithelial ovarian, tubal, and peritoneal cancers (36% versus 24%; P = 0.00013) and a nonsignificant (P = 0.10) reduction in ovarian cancer mortality compared to no screening 7 . The multimodal strategy required repeat CA125 testing and transvaginal ultrasonography at 6-12 week intervals in those with abnormal first-line test results, to ensure high specificity and reduce the number of unnece ssary operations 8 . A highly specific postmenopausal bleeding initially present to a primary care physician and not a gynaecologist. The current management of these women requires transvaginal ultrasonography and, in the absence of a thin distinct endometrial echo, sonohysterography, office hysteroscopy, or endometrial sampling. The value of PapSEEK when these patients are admitted in specialist health-care settings is harder to define. While PapSEEK using a Pap and Tao brush (93%) has similar sensitivity to endometrial sampling (90-100%) 11 , the latter allows for histological assessment, which is key to planning further management.
In conclusion, prospective evaluation in multiple patient settings is required before PapSEEK can be used in routine clinical settings. Nonetheless, PapSEEK remains a promising test with the potential to improve screening for and early detection of gynaecological cancers.
